These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

544 related articles for article (PubMed ID: 33895182)

  • 1. The progression and regression of metabolic dysfunction-associated fatty liver disease are associated with the development of subclinical atherosclerosis: A prospective analysis.
    Liu S; Wang J; Wu S; Niu J; Zheng R; Bie L; Xin Z; Wang S; Lin H; Zhao Z; Wang T; Xu M; Lu J; Chen Y; Xu Y; Wang W; Ning G; Bi Y; Li M; Xu Y
    Metabolism; 2021 Jul; 120():154779. PubMed ID: 33895182
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A significant risk of metabolic dysfunction-associated fatty liver disease plus diabetes on subclinical atherosclerosis.
    Bessho R; Kashiwagi K; Ikura A; Yamataka K; Inaishi J; Takaishi H; Kanai T
    PLoS One; 2022; 17(5):e0269265. PubMed ID: 35639744
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association between nonalcoholic fatty liver disease and subclinical atherosclerosis: a cross-sectional study on population over 40 years old.
    Zheng J; Zhou Y; Zhang K; Qi Y; An S; Wang S; Zhao X; Tang YD
    BMC Cardiovasc Disord; 2018 Jul; 18(1):147. PubMed ID: 30012085
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Associations of subclinical atherosclerosis with nonalcoholic fatty liver disease and fibrosis assessed by non-invasive score.
    Xin Z; Zhu Y; Wang S; Liu S; Xu M; Wang T; Lu J; Chen Y; Zhao Z; Wang W; Ning G; Bi Y; Xu Y; Li M
    Liver Int; 2020 Apr; 40(4):806-814. PubMed ID: 31820847
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metabolic-associated fatty liver disease in relation to site-specific and multiple-site subclinical atherosclerosis.
    Wang X; Zhang R; Man S; Lv J; Yu C; Yin J; Wang X; Deng Y; Wang B; Li L; Pang Y
    Liver Int; 2023 Aug; 43(8):1691-1698. PubMed ID: 37337780
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New definition of metabolic dysfunction-associated fatty liver disease with elevated brachial-ankle pulse wave velocity and albuminuria: a prospective cohort study.
    Wang J; Liu S; Cao Q; Wu S; Niu J; Zheng R; Bie L; Xin Z; Zhu Y; Wang S; Lin H; Wang T; Xu M; Lu J; Chen Y; Xu Y; Wang W; Ning G; Xu Y; Li M; Bi Y; Zhao Z
    Front Med; 2022 Oct; 16(5):714-722. PubMed ID: 35507246
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metabolic dysfunction-associated fatty liver disease increased the risk of subclinical carotid atherosclerosis in China.
    Lei F; Wang XM; Wang C; Huang X; Liu YM; Qin JJ; Zhang P; Ji YX; She ZG; Cai J; Li HP; Zhang XJ; Li H
    Front Endocrinol (Lausanne); 2023; 14():1109673. PubMed ID: 37082131
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Autonomic dysfunction assessed by EZSCAN and subclinical atherosclerosis.
    Sun J; Zhang Y; Xu B; Lv X; Ding L; Chen Y; Sun W; Lu J; Xu M; Bi Y; Ning G
    J Diabetes; 2014 Sep; 6(5):409-16. PubMed ID: 24506497
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Advanced fibrosis associates with atherosclerosis in subjects with nonalcoholic fatty liver disease.
    Chen Y; Xu M; Wang T; Sun J; Sun W; Xu B; Huang X; Xu Y; Lu J; Li X; Wang W; Bi Y; Ning G
    Atherosclerosis; 2015 Jul; 241(1):145-50. PubMed ID: 25988358
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transition patterns of metabolic dysfunction-associated fatty liver disease status in relation to arterial stiffness progression: a health check-up cohort study.
    Liu L; Wang C; Deng S; Yuan T; Zhu X; Deng Y; Qin Y; Wang Y; Yang P
    Sci Rep; 2023 Jun; 13(1):9690. PubMed ID: 37322025
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of diabetes on subclinical atherosclerosis and major cardiovascular events in individuals with and without non-alcoholic fatty liver disease.
    Wang B; Zhao Z; Liu S; Wang S; Chen Y; Xu Y; Xu M; Wang W; Ning G; Li M; Wang T; Bi Y
    Diabetes Res Clin Pract; 2021 Jul; 177():108873. PubMed ID: 34051282
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of Fetuin-B with Subclinical Atherosclerosis in Obese Chinese Adults.
    Li Z; He C; Liu Y; Wang D; Lin M; Liu C; Shi X; Chen Z; Li X; Yang S; Li W
    J Atheroscler Thromb; 2020 May; 27(5):418-428. PubMed ID: 31527322
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Arterial stiffness progression in metabolic dysfunction-associated fatty liver disease subtypes: A prospective cohort study.
    Liu L; Zhou Y; Deng S; Yuan T; Yang S; Zhu X; Wang C; Wang Y
    Nutr Metab Cardiovasc Dis; 2024 Aug; 34(8):1890-1900. PubMed ID: 38658222
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of all-cause mortality associated with non-alcoholic fatty liver disease and metabolic dysfunction-associated fatty liver disease in Taiwan MJ cohort.
    Cheng WC; Chen HF; Cheng HC; Li CY
    Epidemiol Health; 2024; 46():e2024024. PubMed ID: 38317531
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nonalcoholic fatty liver disease is associated with atherosclerosis in middle-aged and elderly Chinese.
    Huang Y; Bi Y; Xu M; Ma Z; Xu Y; Wang T; Li M; Liu Y; Lu J; Chen Y; Huang F; Xu B; Zhang J; Wang W; Li X; Ning G
    Arterioscler Thromb Vasc Biol; 2012 Sep; 32(9):2321-6. PubMed ID: 22814750
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The impact of concomitant hepatitis C virus infection on liver and cardiovascular risks in patients with metabolic-associated fatty liver disease.
    Tsai PS; Cheng YM; Wang CC; Kao JH
    Eur J Gastroenterol Hepatol; 2023 Nov; 35(11):1278-1283. PubMed ID: 37773778
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The association of fatty pancreas with subclinical atherosclerosis in nonalcoholic fatty liver disease.
    Ozturk K; Dogan T; Celikkanat S; Ozen A; Demirci H; Kurt O; Turker T; Yilmaz Y; Uygun A
    Eur J Gastroenterol Hepatol; 2018 Apr; 30(4):411-417. PubMed ID: 29309395
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of metabolic dysfunction-associated fatty liver disease with systemic atherosclerosis: a community-based cross-sectional study.
    Zhang Y; Xia Z; Cai X; Su X; Jin A; Mei L; Jing J; Wang S; Meng X; Li S; Wang M; Wei T; Wang Y; He Y; Pan Y
    Cardiovasc Diabetol; 2023 Dec; 22(1):342. PubMed ID: 38093371
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of MAFLD and NAFLD on arterial stiffness: A longitudinal cohort study.
    Yoo TK; Lee SW; Lee MY; Choi H; Sung KC
    Nutr Metab Cardiovasc Dis; 2024 Jul; 34(7):1769-1778. PubMed ID: 38644081
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevalence and risk factors of metabolic associated fatty liver disease among people living with HIV in China.
    Liu D; Shen Y; Zhang R; Xun J; Wang J; Liu L; Steinhart C; Chen J; Lu H
    J Gastroenterol Hepatol; 2021 Jun; 36(6):1670-1678. PubMed ID: 33140878
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.